Summary of COVID-19 rNAPc2 studies

1. Hess et al., Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial

156 patient rNAPc2 late treatment RCT: 65% higher mortality (p=0.32).
RCT 160 hospitalized COVID-19 patients showing no significant improvements with rNAPc2 (recombinant nematode anticoagulant protein c2) vs. heparin.
Aug 2023, Arteriosclerosis, Thrombosis, and Vascular Biology, https://www.ahajournals.org/doi/10.1161/ATVBAHA.122.318748, https://c19p.org/hess2